At the news
? NEUTRALIMPACT 3/10 SC 13G filed Nov 10, 2026 at 09:33 ET
State Street Corporation filed a Schedule 13G disclosing a 5.0% passive stake in Vanda Pharmaceuticals as of September 30, 2026, with 3,010,531 shares held. This is a new filing by State Street, adding to existing institutional interest from BlackRock (5.9%) and Millennium Management (7.0%). The passive filing indicates no activist intent, but the presence of three large asset managers with 5%+ stakes signals notable institutional conviction in the company.
- State Street Corp filed a new Schedule 13G disclosing a 5.0% passive stake in Vanda Pharmaceuticals
- State Street holds 3,010,531 shares as of September 30, 2026
- The filing certifies passive intent under Rule 13d-1(b), with no control or influence purpose
- State Street joins BlackRock (5.9%) and Millennium Management (7.0%) as 5%+ holders
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access